Results 161 to 170 of about 32,996 (302)

Biological Sex and Chronic Rhinosinusitis Diagnosis and Biomarkers. [PDF]

open access: yesJAMA Otolaryngol Head Neck Surg
Chiu RG   +7 more
europepmc   +1 more source

The Need to Promote Olfactory Health in Public Health Agendas Across the Globe

open access: yesClinical Otolaryngology, EarlyView.
ABSTRACT Background A good sense of smell is essential for physical and mental health, and social wellbeing; however, across the globe, regardless of the setting, national public health agendas never consider smell health. This review aims to summarise the wide‐reaching impact of smell health in public health. Methods Narrative review of the literature
Carl Martin Philpott   +5 more
wiley   +1 more source

Feasibility of Treating Eosinophilic Chronic Rhinosinusitis Using Short-Chain Fatty Acids. [PDF]

open access: yesLaryngoscope
Epithelial cell‐derived cytokines including thymic stromal lymphopoietin (TSLP) are important in the pathogenesis of chronic rhinosinusitis with nasal polyps. We demonstrate the inhibitory effect of TSLP production in airway epithelial cells and eosinophil survival by short‐chain fatty acids (SCFAs) as a potential new strategy to reduce nasal polyps ...
Gozawa R   +12 more
europepmc   +2 more sources

Modifiable Risk Factors for Symptom Burden in Chronic Rhinosinusitis With Nasal Polyps: The Role of Obesity and Sleep Apnoea

open access: yesClinical Otolaryngology, EarlyView.
ABSTRACT Objective To identify sociodemographic and clinical predictors of symptom severity and quality of life (QoL) impairment in patients with chronic rhinosinusitis with nasal polyps (CRSwNP), diagnosed according to the latest EPOS 2020 criteria. Study Design Cross‐sectional analytical study.
Javier Modesto García‐Fernández   +5 more
wiley   +1 more source

Characteristics of Adolescents With Uncontrolled Severe Asthma Starting Dupilumab: The PEDIASTHMA Registry

open access: yes
Allergy, EarlyView.
Stéphanie Wanin   +12 more
wiley   +1 more source

Incidence, Risk Factors, and Management of Conjunctivitis in Atopic Dermatitis Patients Treated With Dupilumab or Tralokinumab: Results From a Multicenter, Observational, Retrospective Study

open access: yesInternational Journal of Dermatology, EarlyView.
ABSTRACT Background Conjunctivitis is among the most frequent adverse events (AEs) emerged in clinical trials for all biologic drugs approved for atopic dermatitis (AD). However, real‐world comparative data on the incidence, risk factors, and management of conjunctivitis remain limited.
Luca Potestio   +50 more
wiley   +1 more source

High Remission Rate in Eosinophilic Chronic Rhinosinusitis Following More Than Two Years of Dupilumab Therapy. [PDF]

open access: yesLaryngoscope Investig Otolaryngol
ABSTRACT Objective This study aimed to evaluate the clinical remission rate and changes in medication use in patients with eosinophilic chronic rhinosinusitis (ECRS) treated with dupilumab for > 2 years. Methods This retrospective study included 19 patients with ECRS who received dupilumab therapy for > 2 years. The nasal polyp, Lund–Mackay on sinus CT,
Kamimura S   +4 more
europepmc   +2 more sources

Home - About - Disclaimer - Privacy